Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Newly Aligned Teams Sped US FDA’s Drug Quality Reviews Over Pandemic Hurdles

Executive Summary

Realignment played key role in keeping assessments on track as COVID-19 buckled pharmaceutical supply and distribution chains and prevented inspections.

You may also be interested in...



How US FDA’s Pharma Quality Office Fared In Pandemic’s Second Year

OPQ Director Kopcha looks back at a year that travel restrictions made especially challenging for application reviews, site surveillance, IT support and sleep. And ahead to new challenges around supply chain transparency and resilience.

Initial List Of US Essential Medicines Focuses On Acute Care

US FDA excludes chronic care products from list of medicines bolstered by domestic production investment and federal procurement requirements.

Can 'Buy American’ Executive Order Shake Up ‘Dickensian’ Manufacturing Dynamics?

The Trump administration’s move to strengthen domestic manufacture of essential medicines raises a lot of questions – and industry’s ire.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel